Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Cell. 2022 Apr 28;185(9):1572-1587.e11. doi: 10.1016/j.cell.2022.03.037. Epub 2022 Mar 28.
The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.1., and BA.2) could jeopardize the efficacy of SARS-CoV-2 vaccines. We evaluated in mice the protective efficacy of the Moderna mRNA-1273 vaccine against BA.1 before or after boosting. Whereas two doses of mRNA-1273 vaccine induced high levels of neutralizing antibodies against historical WA1/2020 strains, lower levels against BA.1 were associated with breakthrough infection and inflammation in the lungs. A primary vaccination series with mRNA-1273.529, an Omicron-matched vaccine, potently neutralized BA.1 but inhibited historical or other SARS-CoV-2 variants less effectively. However, boosting with either mRNA-1273 or mRNA-1273.529 vaccines increased neutralizing titers and protection against BA.1 and BA.2 infection. Nonetheless, the neutralizing antibody titers were higher, and lung viral burden and cytokines were slightly lower in mice boosted with mRNA-1273.529 and challenged with BA.1. Thus, boosting with mRNA-1273 or mRNA-1273.529 enhances protection against Omicron infection with limited differences in efficacy measured.
奥密克戎谱系变异株(BA.1、BA.1.1 和 BA.2)中有大量刺突突变,这可能会危及 SARS-CoV-2 疫苗的功效。我们在小鼠中评估了 Moderna mRNA-1273 疫苗在加强针之前或之后对 BA.1 的保护效力。虽然两剂 mRNA-1273 疫苗可诱导针对历史 WA1/2020 株的高水平中和抗体,但针对 BA.1 的抗体水平较低与肺部突破性感染和炎症相关。用与奥密克戎匹配的疫苗 mRNA-1273.529 进行初级疫苗接种系列,可有效地中和 BA.1,但对历史或其他 SARS-CoV-2 变体的抑制作用较弱。然而,无论用 mRNA-1273 还是 mRNA-1273.529 疫苗加强免疫都能提高中和滴度并预防 BA.1 和 BA.2 感染。尽管如此,在接受 BA.1 挑战时,用 mRNA-1273.529 加强免疫的小鼠的中和抗体滴度更高,肺部病毒载量和细胞因子水平略低。因此,用 mRNA-1273 或 mRNA-1273.529 加强免疫可增强对奥密克戎感染的保护作用,但其功效差异有限。